Billing errors at two of the three Thomas Jefferson University Hospitals in 2008 and 2009 resulted in Medicare overpaying the hospital system $43,438, according to a report released Thursday by the Department of Health and Human Services Office of Inspector General.
With the federal budget tight and cries from all corners about wasteful spending, HHS and the Justice Department have increased their efforts to track where money goes and whether there was any fraud.
This case involved no apparent fraud, but it did touch a problematic area for hospitals - readmissions and the errors that cause them. Public and private insurers want to reduce them for the sake of patients and to save money.
Federal auditors found mistakes in four of the 133 same-day readmissions that were reviewed. Three occurred at Thomas Jefferson University Hospital and one at Jefferson Hospital for Neuroscience. The facilities incorrectly billed the second admission as a separate inpatient stay instead of a continuous stay based on the first admission, resulting in the overpayment.
The report focused on readmissions and was not an overall assessment of all Medicare reimbursement claims submitted by Jefferson, which has returned the extra money.
In a letter attached to the report, Jefferson CEO Thomas Lewis said the three-hospital system had reminded employees of the existing billing policies and submitted a plan "to prevent recurrence of said same-day readmission billing deficiencies."
Lewis will retire, effective June 30, and chief operating officer David McQuaid will keep that title and add that of president.
The full OIG report is here.
- Pharmalot
- The Placebo Effect
- New York Times/Prescriptions
- Wall Street Journal/Health blog
- Financial Times
- Cafe Pharma
- Pharma Marketing
- Bio Century
- Bio Space
- Pharma Live
- Monday Morning
- In The Pipeline
- U.S. Department of Health and Human Services
- Food and Drug Administration
- Centers for Medicare and Medicaid
- Office of Inspector General, Health and Human Services
- OIG Most-wanted list of fugitives
- Centers for Disease Control and Prevention
- Securities and Exchange Commission/Edgar filings
- U.S. Attorney's Office/Eastern Pennsylvania, health-care fraud
- Clinical Trials
- Pharmaceutical Research and Manufacturers of America
- BIO
- Pennsylvania Association of Medical Suppliers
- Jersey Association of Medical Equipment Services
- Science Center
- American Health Lawyers Association
- Drug and Device Law
- Orange Book blog
- Taxpayers Against Fraud
- Adolor
- Almac
- AmerisourceBergen
- AstraZeneca
- Auxilium
- Bayer
- Celgene
- Cephalon
- Endo
- GlaxoSmithKline
- Johnson & Johnson
- Kensey Nash
- Lannett
- Merck
- Pfizer
- Roche
- Sanofi-aventis
- Shire
- Stryker
- Synthes
- Teva
- ViroPharma
- West








David Sell covers the pharmaceutical industry and related topics for The Inquirer’s Business Department. David has been a reporter and editor for more than 20 years. Contact him with tips and suggestions about news from the drug industry and the people who define an industry that touches nearly everyone and employs tens of thousands in the Philadelphia area.
Like David Sell and PhillyPharma